The Battle For Shire PLC

Buyers are fighting over Shire PLC (LON: SHP).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shire (LSE: SHP) (NASDAQ:SHPG.US) has been the subject of bid speculation for some time now. So it came as no surprise when the company revealed today that it was in takeover talks with US drug maker AbbVie Inc

AbbVie makes the rheumatoid arthritis drug Humira, and a deal between the two companies would create a world leading specialist in rare disease treatments.

However, the two companies have been in talks for some time now, but there has been no agreement so far. What’s more, there is no guarantee the discussions will lead to a transaction.

Plenty of suitors 

shireNevertheless, it is also possible that other suitors will emerge for Shire. Indeed, during the last few weeks rumours have been flying around the City that another US biotech giant, Allergan, will pounce on the company.

Allergan is one of the world’s leading Botox makers and the company is currently trying to fight off a hostile bid from peer Valeant.

It is thought that if Valeant were to successfully acquire Allergan, Allergan would be torn to pieces and sold off to make a quick buck. So, to protect stakeholders, Allergan is weighing up deals to effectively buy its way out of the deal.  

Shareholders will benefit

A deal between Shire and Allergan would actually be great news for the shareholders of both companies.

You see, the management teams at Shire and Allergan are considered to be the best in the business — and the share prices of both companies stand testament to this. Over the past five years, Shire and Allergen have seen their share prices surge 350% and 250% respectively.

Further, a deal would mean that the combined company would have leading market shares in aesthetics, ophthalmology, and orphan/rare diseases.

Initial estimates did suggest that Allergan could offer up to $41bn (£24bn) for Shire, but after recent gains Shire is now worth a lot more.

Plans of its own

While suitors are circling Shire, the company has plans of its own. There is talk that Shire could pay up to $4bn in cash for US-based NPS pharma. Shire has recently inked a deal with Citigroup, which will see the bank provide a war chest of $5bn to the company.

Once again, a deal between Shire and NPS would be a boon for the company’s shareholders. NPS’s lead product, Gattex — designed for the treatment of short bowel syndrome — fits across both Shire’s rare disease and gastrointestinal platforms. A merger of the two companies would accelerate Shire’s plans to expand within the rare disease treatment market.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert does not own any share mentioned within this article. The Motley Fool has recommended shares in Shire.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »

Investing Articles

What might the 5-year price chart tell us about BT shares?

Christopher Ruane considers what clues the long-term performance of BT shares might offer him about business performance and whether to…

Read more »